Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 3/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920688 | 0.81 | KEAP1 (0.62) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL113812 | 0.80 | KEAP1 (1.00) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL29744459 | 0.80 | KEAP1 (1.00) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| Hydrochloric Acid SCHEMBL919985 | 0.78 | KEAP1 (0.96) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL18149209 | 0.78 | KEAP1 (0.59) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL4841196 | 0.77 | KEAP1 (0.57) | KEAP1NFE2L2POLBHPGDTSHR | |
| SCHEMBL919984 | 0.76 | KEAP1 (0.71) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL31048928 | 0.76 | KEAP1 (0.71) | KEAP1NFE2L2CTNNB1TCF7L2POLB | |
| SCHEMBL14395311 | 0.76 | KEAP1 (0.56) | KEAP1NFE2L2RAB9APKM | |
| SCHEMBL166218 | 0.74 | KEAP1 (0.69) | KEAP1NFE2L2POLBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287068-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4403175-A2 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11993597-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4141005-B1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC (US) | 2024-04-03 | — | — | EP | disclosed |
| EP-4141005-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3679040-B1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220213101-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2022-07-07 | — | — | US | disclosed |
| US-11306087-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3679040-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207766-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2020-07-02 | — | — | US | disclosed |
| US-10640504-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2019051291-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213101-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 271/4885NFE2L2 2542/4885CTNNB1 612/4885 |
| US-20200207766-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 234/4885NFE2L2 2713/4885CTNNB1 790/4885 |
| US-20240287068-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 271/4885NFE2L2 2542/4885CTNNB1 612/4885 |
| US-11993597-B2 | Inhibitors of KRAS G12C and methods of using the same | KRAS, NRAS, HRAS | KEAP1 271/4885NFE2L2 2542/4885CTNNB1 612/4885 |
| US-10640504-B2 | Inhibitors of KRAS G12C and methods of using the same | KRAS, NRAS, HRAS | KEAP1 271/4885NFE2L2 2542/4885CTNNB1 612/4885 |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 271/4885NFE2L2 2542/4885CTNNB1 612/4885 |
| US-11306087-B2 | Inhibitors of KRAS G12C and methods of using the same | KRAS, NRAS, HRAS | KEAP1 234/4885NFE2L2 2713/4885CTNNB1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.